ADG 116
Alternative Names: ADG-116Latest Information Update: 28 Apr 2025
At a glance
- Originator Adagene
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Regulatory T-lymphocyte inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy) in China (IV)
- 31 Aug 2023 Efficacy and adverse events data from phase Ib/II trial in Solid tumours released by Adagene
- 31 Aug 2023 Adagene plans a phase II trial in Solid tumours